dipyridamole has been researched along with Carcinoma, Anaplastic in 6 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole (DPM), a nucleoside membrane transport inhibitor, enhanced the cytotoxicity of cisplatin (DDP) for human ovarian carcinoma 2008 cells by a factor of 4." | 7.68 | Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. ( Chan, TC; Howell, SB; Jekunen, A; Sanga, R; Vick, J, 1992) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 5.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| " The toxic effects of thymidylate synthase inhibition may be prevented by salvage of exogenous thymidine." | 5.27 | Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. ( Curtin, NJ; Harris, AL, 1988) |
| "Dipyridamole (DPM), a nucleoside membrane transport inhibitor, enhanced the cytotoxicity of cisplatin (DDP) for human ovarian carcinoma 2008 cells by a factor of 4." | 3.68 | Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. ( Chan, TC; Howell, SB; Jekunen, A; Sanga, R; Vick, J, 1992) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 1.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| " The toxic effects of thymidylate synthase inhibition may be prevented by salvage of exogenous thymidine." | 1.27 | Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. ( Curtin, NJ; Harris, AL, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, HY | 1 |
| Lu, TW | 1 |
| Liang, HL | 1 |
| Hsu, WH | 1 |
| Sung, YW | 1 |
| Lee, MY | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Jekunen, A | 1 |
| Vick, J | 1 |
| Sanga, R | 1 |
| Chan, TC | 1 |
| Howell, SB | 1 |
| Wyngaarden, JB | 1 |
| Curtin, NJ | 1 |
| Harris, AL | 1 |
| Schmähl, D | 1 |
| Höllenriegel, K | 1 |
| Mundt, D | 1 |
6 other studies available for dipyridamole and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study.
Topics: Aspirin; Carcinoma; Diabetes Mellitus, Type 2; Dipyridamole; Humans; Liver Neoplasms; Platelet Aggre | 2022 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Topics: Carcinoma; Cell Membrane Permeability; Cisplatin; Dipyridamole; Drug Synergism; Female; Humans; Ovar | 1992 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Carcinoma; Colorectal Neoplasms; Dipyridamole; Humans; Interfero | 1989 |
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Topics: Carcinoma; Cell Survival; Dipyridamole; DNA; Drug Synergism; Folic Acid; Folic Acid Antagonists; Hum | 1988 |
[Investigations in multi-step-therapy of cancer (according to M. v. Ardenne) in animal experiments (author's transl)].
Topics: Animals; Ascorbic Acid; Benzopyrenes; Carcinoma; Carcinoma, Ehrlich Tumor; Dipyridamole; Female; Glu | 1974 |